New hope for teens with uncontrollable hives
NCT ID NCT06053801
Summary
This study looked at the safety and real-world effectiveness of an injectable medication called Xolair (omalizumab) for Chinese teenagers with chronic spontaneous urticaria (CSU), a condition causing persistent, itchy hives. It involved 55 adolescents whose hives were not adequately controlled by standard antihistamine pills. Researchers monitored participants for 16 weeks to see if the treatment reduced itching and hives and improved their quality of life, while carefully tracking any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Fuzhou, Fujian, 350025, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510091, China
-
Novartis Investigative Site
Changsha, Hunan, 410008, China
-
Novartis Investigative Site
Nantong, Jiangsu, 226000, China
-
Novartis Investigative Site
Dalian, Liaoning, 116000, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310001, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310006, China
-
Novartis Investigative Site
Wenzhou, Zhejiang, 325000, China
-
Novartis Investigative Site
Beijing, 100069, China
-
Novartis Investigative Site
Shanghai, 200443, China
Conditions
Explore the condition pages connected to this study.